Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US, Canada Setting Trend For Global Cybersecurity Guidance

Executive Summary

A draft IMDRF guidance released this month aims to set the trend for how regulators around the world oversee cybersecurity of medical devices. According to experts, the document also foreshadows what sponsors can expect from the US FDA in areas such as developing a software bill of materials, as the agency updates its own cybersecurity guidances.

You may also be interested in...



A Deep Dive With US FDA’s Suzanne Schwartz: COVID-19, Cybersecurity, Device Shortages, And More

As head of the device center’s emergency response program, Schwartz oversees a broad range of issues, from medical device shortages to cybersecurity vulnerabilities. We talk to her in this Medtech Insight profile.

International Regulators Issue Final Cybersecurity Guidance

A final IMDRF guidance on medical device cybersecurity reinforced US and Canadian regulatory thinking on issues such as a total product life cycle approach, shared responsibility and creating a software bill of materials.

Cybersecurity: Guidance Docs To Come, But Legacy Devices Still A Challenge

Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT125807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel